About this webinar
In this webinar, our scientific team introduces the TRIDENT™ platform and demonstrates how it overcomes the key limitations of traditional site-specific conjugation methods.
You’ll see how TRIDENT™ delivers consistent high titers, flexible DAR control, and genetic stability—without antibody engineering.
Whether you’re working on ADCs, multispecifics, or next-generation biologics, this session will show you how to accelerate development with confidence.
What you’ll learn
Why traditional methods fall short
Understand the cost, complexity, and development risks introduced by conventional site-specific conjugation approaches.
Precision without antibody re-engineering
See how TRIDENT™ enables controlled integration while preserving the native antibody structure.
Higher titers with flexible DAR control
Explore performance data demonstrating strong expression, stability, and support for DAR 2, 4, 6, and 8.
Stability from pool to clone
Learn how predictive pool performance and targeted integration help reduce variability during cell line development.
Applications across advanced biologics
Discover how the platform supports ADCs, multispecifics, and other next-generation therapeutic modalities.
Downloadable resources
DEP rescue checklist
A practical checklist for identifying expression, secretion, purification, and analytical risks before starting a rescue workflow.
Rapid rescue workflow overview
A one-page visual summary of Celltheon’s DEP rescue workflow, from molecule intake to rescue recommendation.
Difficult protein intake template
A structured template for sharing sequence, format, expression history, prior data, and program goals with the Celltheon team.
Watch webinar
